Glossary
Interstitial lung disease
In several autoimmune diseases it's the lungs that decide the outlook rather than the joints or the muscles. That's why this gets looked for rather than waited for. Most people who have it stay stable on treatment, and the minority who don't are the reason anybody checks early.
What the research found.
One German study followed 3257 people with systemic sclerosis and tracked what happened to their lungs. By the end, 47.6 percent had interstitial lung disease, 15.2 percent had it alongside pulmonary hypertension, and 6.5 percent had pulmonary arterial hypertension. Five-year survival was 96.4 percent in those with no lung involvement at all.
One review pooled 27 groups of patients with dermatomyositis, holding 2579 people between them, of whom 620 had the fast-moving form. Lactate dehydrogenase separated the two groups most clearly of anything measured. The mean difference came out at 75.94, with the true value running somewhere from 64.20 to 87.67.
One study followed 114 people with myositis-related lung disease, where all-cause mortality over the follow-up came to 27.2 percent. Four things independently predicted death in that group. They were an acute or subacute course, a lower forced vital capacity, age, and a clinically amyopathic diagnosis rather than polymyositis.
One study followed 103 people who had anti-Jo-1 antibodies and lung disease, and ten-year survival in that group was 68 percent. Non-specific interstitial pneumonia was the commonest scan picture, at 52 percent. Restriction showed on lung function testing in 98 percent of them, which is very nearly everybody.
One study followed 198 people with inflammatory muscle disease at a Portuguese center, and 34.8 percent of them had interstitial lung disease. Most of the scan pictures stayed stable over time, at 89.6 percent of the group. Gas transfer improved over the follow-up period, at a P value of 0.022.
What it is
Interstitial lung disease is swelling or scarring of the tissue between the air sacs of the lung. That tissue has a name, and it's called the interstitium. It's where oxygen crosses from the air you breathe into your blood, so when it swells or scars the lung stiffens and that crossing gets harder.
So the symptoms of it aren't what most people would expect from a lung problem at all. There is no pain to speak of, which throws people. What there is instead is breathlessness, usually on effort before anything else, and a dry cough that won't settle down.
Which diseases cause it, and how often
Several autoimmune diseases cause it, and they do it at very different rates. Those differences are worth knowing, because the number that applies to you depends on which diagnosis you have. One Korean study reviewed 751 people with systemic sclerosis, where interstitial lung disease was the commonest organ problem at 52.7 percent. Reflux came next at 32.9 percent, and pulmonary arterial hypertension at 13.6 percent.
One German study followed 3257 people with systemic sclerosis, where it was present in 34.5 percent at the start. By the end of follow-up that had reached 47.6 percent. Another 15.2 percent had it alongside pulmonary hypertension, and 6.5 percent had pulmonary arterial hypertension without it.
One Portuguese study followed 198 people with inflammatory muscle disease, and 34.8 percent of them had interstitial lung disease. In antisynthetase syndrome the figure is higher still. One Chinese study of 88 people with that syndrome found lung disease in 90 percent of them, which made it the commonest feature of the illness, ahead of the muscle involvement it's named for.
Why it decides the outlook
This is why the lungs get checked rather than waited on, and the survival figures are the reason. The German study of 3257 people gives the clearest comparison. Five-year survival was 96.4 percent in those with no lung involvement at all, survival differed significantly across the groups, and it was worst in those who had both lung disease and pulmonary hypertension together.
Three things in that study went with lower death rates. Being female came with a hazard ratio of 0.3, a higher body mass index with 0.9, and better gas transfer on lung testing with 0.98. The gas transfer figure is the one a clinic can watch over time.
One study followed 114 people with myositis-related lung disease, where all-cause mortality was 27.2 percent. Four things predicted death in that group on their own. They were an acute or subacute course, a lower forced vital capacity, age, and a clinically amyopathic diagnosis rather than polymyositis.
The fast-moving form
Most interstitial lung disease develops over years, and a minority worsens over weeks. That second form is where the risk concentrates. In that study of 114 people the disease was acute or subacute in 59 of them and chronic in 55, and survival was much lower in the acute or subacute group, at P under 0.001.
One review went looking for what predicts it. It pooled 27 groups of people with dermatomyositis, holding 2579 people between them, of whom 620 had the fast-moving form. Lactate dehydrogenase separated the groups most clearly, at a mean difference of 75.94 whose true value the study puts between 64.20 and 87.67, at P under 0.00001.
Two other tissue damage markers came out much weaker than that. Aspartate aminotransferase came out at 24.35, with the true value running from 8.74 to 39.96. Alanine aminotransferase came out at 26.20, from 10.04 to 42.36.
Two clinical predictors stood out from the rest. Fever came with an odds ratio of 3.16, from 2.12 to 4.72. A positive anti-Ro-52 came with 2.87, from 1.52 to 5.40, and fever is the one a reader can notice for themselves.
How to read those numbers
This is the most important qualification on the page, and it applies to every figure in the section above. It's worth reading through twice before moving on. That review reports links to outcome, written as differences between groups, and it gives no lactate dehydrogenase threshold anywhere.
It gives no catch rate, no clearing rate, and no likelihood ratio, and that holds for every one of its predictors. So the numbers say which groups differ on average rather than what your own result means. A raised lactate dehydrogenase in one person is neither a diagnosis nor a prediction, and what it is instead is a reason for the people looking after you to look further.
The scan pictures
The picture on a scan holds information, and the two names below are worth recognizing. They'll appear on your own report if you have one. Non-specific interstitial pneumonia is the commonest of them in this setting, and one study of 103 people with anti-Jo-1 antibodies found it in 52 percent.
Next came that picture overlapping organizing pneumonia, at 22 percent, and restriction on lung function testing was present in 98 percent. One study of 198 people with inflammatory muscle disease found that picture leading too. Non-specific interstitial pneumonia was there in 69.5 percent of those with lung disease, so one picture dominates in both groups.
Which antibody you have changes what the scan shows. One study looked at 108 people with antisynthetase syndrome and lung disease, where organizing pneumonia led in the anti-EJ group at 78.2 percent. That beat the anti-PL-7 group at P under 0.001 and the anti-PL-12 group at P equals 0.025.
What usually happens
The studies here point more toward stability than toward decline, and that's worth saying beside the survival figures. Both of those things are true at once. That Portuguese study of 198 people found most scan pictures stayed stable, at 89.6 percent, with gas transfer improving over follow-up at P equals 0.022.
Forced vital capacity was stable or improved, at P equals 0.097, which doesn't clear the usual threshold. One study re-examined 34 people with myositis-associated lung disease after more than a year, finding 26 stable and 8 deteriorating. Six of the deteriorating group needed home oxygen. Two things predicted that decline on their own, which were a positive anti-PL-7 test and a lower percent predicted forced vital capacity.
One study of 108 people with antisynthetase syndrome and lung disease reports no deaths at all. The median follow-up there was 10.7 months, which is a short window and worth reading as one. So the honest summary of all this comes in two halves. This is a serious complication in which most people are stable on treatment, and the fast-moving form is a different situation with different numbers.
The blood tests
One point here catches people out regularly, and the muscle pages on this site make it too. It comes down to which of the two tests is being read. Creatine kinase is the blood test that reflects muscle damage, and in one national cohort it stayed low even in people who had lung disease.
The median in that group was 193.5 units per liter, and C-reactive protein stayed low as well. What was raised instead was lactate dehydrogenase, up in 91.7 percent of that whole group. That's the test the review found separated the fast-moving form most clearly, which is why it turns up twice on this page.
So a normal creatine kinase says something true and useful about your muscles. It says nothing at all about your lungs. Those are two different questions, and only one of them is being answered by that particular result.
What to report
The list of things worth reporting is short, and it's mostly about breathing. None of it is a reason to panic, and all of it is worth a phone call rather than a wait. New breathlessness counts, and so does breathlessness that's worse than it used to be.
A dry cough that won't settle down counts too. So does getting out of breath on stairs or slopes when you didn't before, which is easy to explain away and worth not explaining away. Fever belongs on the list as well, because it was one of the two clinical predictors of the fast-moving form.
Anything that feels like a chest infection belongs on that list too. None of those on its own means something bad is happening. All of them are worth reporting rather than watching, which is a higher standard than most of this site asks for.
Common misconceptions.
Myth. This is a lung disease, so it's the lung doctors' problem.
Reality. It's a complication of your autoimmune disease, and it changes how that disease gets treated. One study followed 198 people on immune-suppressing treatment, and gas transfer improved over follow-up at P equals 0.022, while most scan pictures stayed stable at 89.6 percent. So the treatment aimed at the illness is part of what happens to the lungs.
Myth. Everyone with it gets worse.
Reality. Most don't get worse, on the studies gathered here. One group of 198 people had stable scan pictures in 89.6 percent over time, and one of 34 people followed for more than a year found 26 stable and 8 deteriorating. One group of 108 people had no deaths at all over a median 10.7 months. The fast-moving form is where risk concentrates, and it's the minority.
Myth. A normal muscle blood test means my lungs are fine.
Reality. Those are separate questions, and mixing them up is easy to do. One national cohort found creatine kinase stayed low even in people who had lung disease, while what was raised instead was lactate dehydrogenase, in 91.7 percent of the group. One review found that test separated the fast-moving form most clearly, at a mean difference of 75.94.
Myth. The numbers on this page tell me what my own result means.
Reality. They don't, and this is worth saying plainly. The review behind the fast-moving figures reports links to outcome, written as differences between groups, and it gives no threshold for any test. It gives no catch rate, no clearing rate, and no likelihood ratio, so the numbers say which groups differ rather than what your result means.
Myth. All these lung diseases look alike on a scan.
Reality. They don't, and the picture holds information of its own. One study of 103 people with anti-Jo-1 antibodies found most had non-specific interstitial pneumonia at 52 percent, with that picture plus organizing pneumonia next at 22 percent. A second study of 108 people with antisynthetase syndrome found organizing pneumonia leading in the anti-EJ group, at 78.2 percent, which beat two other antibody groups.
Related terms.
- Amyopathic dermatomyositis, where the fast-moving form is commonest.
- Antisynthetase syndrome, where lung disease reaches 90 percent.
- Systemic sclerosis, where it's the commonest organ problem.
- Pulmonary hypertension, the other lung problem these diseases cause.
Questions patients ask.
What is interstitial lung disease?
Swelling or scarring of the tissue between the air sacs of the lung, which is called the interstitium. That's where oxygen crosses from air into blood, so when it swells or scars the lung stiffens and the crossing gets harder. The symptoms are breathlessness and a dry cough rather than pain. That's not what most people expect from a lung problem, and it's part of why it gets missed.
Which autoimmune diseases cause it?
Several do, and they do it at very different rates. One Korean study of 751 people with systemic sclerosis found lung disease in 52.7 percent, which made it the commonest organ problem there. One German study of 3257 people with systemic sclerosis found 47.6 percent by the end of follow-up. One Portuguese study covering 198 people with inflammatory muscle disease found 34.8 percent of them affected.
How much does it change the outlook?
It's often the thing that decides the outlook more than anything else. One German study followed 3257 people with systemic sclerosis, and five-year survival was 96.4 percent in those with no lung involvement at all. Survival was worst of all in the group who had lung disease and pulmonary hypertension together. One study followed 114 people with myositis-related lung disease, where all-cause mortality was 27.2 percent.
What is the fast-moving form?
Lung disease that worsens over weeks rather than years, and its formal name is rapidly progressive interstitial lung disease. One study followed 114 people, where an acute or subacute course predicted death on its own and survival was much lower than in the slow form, at P under 0.001. It's the minority of cases, and it's also where nearly all of the risk on this page sits.
What predicts it?
One review pooled 27 groups holding 2579 people with dermatomyositis, of whom 620 had the fast-moving form. Lactate dehydrogenase separated the two groups most clearly of anything measured, at a mean difference of 75.94 from 64.20 to 87.67. Fever predicted it at an odds ratio of 3.16, and anti-Ro-52 at 2.87.
What do the scan pictures mean?
They differ from each other, and which one you have holds real information. One study of 103 people with anti-Jo-1 antibodies found non-specific interstitial pneumonia commonest there, at 52 percent. Another study of 108 people with antisynthetase syndrome found organizing pneumonia leading in the anti-EJ group, at 78.2 percent, which beat two other antibody groups. Your own team can say which picture yours is.
Does treatment help?
The studies here point to stability as the usual course rather than decline. One study followed 198 people on treatment, and scan pictures stayed stable in 89.6 percent of them, with gas transfer improving over follow-up at P equals 0.022. Lung capacity was stable or improved, at P equals 0.097. This page names no treatment at all, because what you're offered is your team's decision.
What should I report?
Anything new about your breathing, and quickly rather than at your next appointment. New or worsening breathlessness counts, a dry cough that won't settle counts, and so does getting out of breath on stairs when you didn't before. Fever belongs on the list too, because it was one of the two clinical predictors of the fast-moving form. All of those are worth reporting rather than watching and waiting.
References.
- Liu T; Ji X; Wei Y et al. Predictors of rapidly progressive interstitial lung disease in anti-MDA5 dermatomyositis: a meta-analysis. Rheumatology (Oxford, England). 2026;65. 10.1093/rheumatology/keag311Systematic review and meta-analysis of 27 cohorts
- Moinzadeh P; Bonella F; Oberste M et al. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis. Chest. 2024;165:132-145. 10.1016/j.chest.2023.08.013Large cohort study of the German Network for Systemic Sclerosis registry
- Fujisawa T; Hozumi H; Kono M et al. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014;9:e98824. 10.1371/journal.pone.0098824Retrospective analysis of 114 consecutive patients diagnosed with interstitial lung disease associated with polymyositis
- Zamora AC; Hoskote SS; Abascal-Bolado B et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir Med. 2016;118:39-45. 10.1016/j.rmed.2016.07.009Fifteen-year cohort of 103 patients identified with anti-Jo-1 positive antisynthetase syndrome and interstitial lung disease
- Correia BP; Campanilho-Marques R; Dourado E et al. Myositis-Associated Interstitial Lung Disease: The Experience of a Tertiary Center. J Clin Med. 2024;13. 10.3390/jcm13206085Retrospective study of 198 patients with idiopathic inflammatory myopathy followed at a Portuguese tertiary centre between June 2016 and March 2024
- Moon KW; Lee SS; Lee YJ et al. Clinical and Laboratory Characteristics and Mortality in Korean Patients with Systemic Sclerosis: A Nationwide Multicenter Retrospective Cohort Study. J Rheumatol. 2018;45:1281-1288. 10.3899/jrheum.171443Journal Article
- Fujisawa T; Hozumi H; Kono M et al. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases. Respir Investig. 2017;55:130-137. 10.1016/j.resinv.2016.09.006Retrospective analysis of 34 patients with interstitial lung disease associated with polymyositis
- Zhan X; Yan W; Wang Y et al. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China. BMC Pulm Med. 2021;21:57. 10.1186/s12890-021-01399-5Retrospective cohort of 108 consecutive patients with antisynthetase syndrome-associated interstitial lung disease at one Beijing hospital
- Muscato G; Morina G; Fagone E et al. Interstitial Lung Disease Secondary to Sjogren's Syndrome and Antisynthetase Syndrome: Converging Disease Trajectories. Medicina (Kaunas). 2025;61. 10.3390/medicina61112044Retrospective study comparing 34 patients with Sjogren's syndrome-associated interstitial lung disease against 33 with antisynthetase syndrome-associated interstitial lung disease
- Tang HS; Tang IYK; Ho RTC et al. Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: a multi-centred retrospective cohort study. Rheumatology (Oxford). 2025;64:212-220. 10.1093/rheumatology/kead671Multicentre retrospective longitudinal cohort of 205 patients meeting Connor's or Solomon's criteria for antisynthetase syndrome
- Mogyoróssy S; Griger Z; Tarr T et al. Management and Prognosis of Anti-MDA5 Dermatomyositis: Insights from a National Multicenter Cohort. Biomedicines. 2026;14. 10.3390/biomedicines14030709Retrospective multicentre study of anti-MDA5 positive Caucasian patients managed at four Hungarian rheumatology centres between 2020 and 2025
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.